Chargement en cours...
(177)Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors
INTRODUCTION: (177)Lutetium-[DOTA°,Tyr(3)]octreotate ((177)Lu-DOTATATE) is a type of peptide receptor radionuclide therapy that garnered FDA approval in January 2018 for the treatment of somatostatin receptor-positive gastroenteropancreatic (GEP) neuroendocrine tumor (NET) patients. The therapy appr...
Enregistré dans:
| Publié dans: | Expert Rev Gastroenterol Hepatol |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7227421/ https://ncbi.nlm.nih.gov/pubmed/31652074 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/17474124.2019.1685381 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|